CompletedPhase 2ACTRN12606000031561

C FEN 0205

a randomised, double-blind, placebo-controlled study assessing the effect of fenofibrate, coenzyme Q10 and their co-administration on ventricular disatolic function in patients with type 2 diabetes

Sponsor

Fournier Laboratory Ireland

Enrollment

125 participants

Start Date

Jun 1, 2003

Study Type

Interventional

Conditions

Type 2 diabetes with left ventricular diastolic dysfunction (LVDD)

Eligibility

Sex: Both males and femalesMin Age: 40 YearssMax Age: 79 Yearss

Inclusion Criteria1

Type 2 diabetes patients with LVDD and LV ejection fraction equal or greater than 50%.

Exclusion Criteria1

Serum creatinine above 130 micromol/l, ALT/AST above 2xULN, CK above 3xULN.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

fenofibrate 80mg + CoEnz Q10 100mg fenofibrate 80mg + CoEnz Q10 200mg fenofibrate 160mg + CoEnz Q10 100mg fenofibrate 160mg + CoEnz Q10 200mg fenofibrate 160mg CoEnz Q10 200mg 6 MONTHS INTERVE

fenofibrate 80mg + CoEnz Q10 100mg fenofibrate 80mg + CoEnz Q10 200mg fenofibrate 160mg + CoEnz Q10 100mg fenofibrate 160mg + CoEnz Q10 200mg fenofibrate 160mg CoEnz Q10 200mg 6 MONTHS INTERVENTION

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000031561